Search

Your search keyword '"Service Maladies infectieuses et tropicales [CHU Toulouse]"' showing total 45 results

Search Constraints

Start Over You searched for: Author "Service Maladies infectieuses et tropicales [CHU Toulouse]" Remove constraint Author: "Service Maladies infectieuses et tropicales [CHU Toulouse]" Topic business.industry Remove constraint Topic: business.industry
45 results on '"Service Maladies infectieuses et tropicales [CHU Toulouse]"'

Search Results

1. Clinical characteristics and outcome of hospitalized patients with SARS-CoV-2 infection at Toulouse University hospital (France). Results from the Covid-clinic-Toul cohort

2. Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML

3. No increased risk of Kaposi sarcoma relapse in patients with controlled HIV‐1 infection after switching protease inhibitor‐based antiretroviral therapy

4. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies

5. CCR5 Blockade in Inflammatory PML and PML-IRIS Associated With Chronic Inflammatory Diseases' Treatments

6. Kaposi’s Sarcoma in Virally Suppressed People Living with HIV: An Emerging Condition

7. Comparison of the first and second waves of coronavirus disease in Toulouse, France

8. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19

9. Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Kinetics and Protection Duration

10. Impact of previous exposure to systemic corticosteroids on unfavorable outcome in patients hospitalized for COVID-19

11. Outcome of patients hospitalized for Covid‐19 and exposure to angiotensin‐converting enzyme inhibitors and angiotensin‐receptor blockers in France: Results of the ACECoV study

12. Neglecting plasma protein binding in COVID-19 patients leads to a wrong interpretation of lopinavir overexposure

13. Sexual transmission of an extensively drug-resistant HIV-1 strain

14. Saliva sampling for diagnosing SARS-CoV-2 infections in symptomatic patients and asymptomatic carriers

15. COVID-19, Virology and Geroscience: A Perspective

16. TLR7 dosage polymorphism shapes interferogenesis and HIV-1 acute viremia in women

17. Kaposi sarcoma among people living with HIV in the French DAT'AIDS cohort between 2010 and 2015

18. Multimorbidity in Elderly Persons According to the Year of Diagnosis of Human Immunodeficiency Virus Infection: A Cross-sectional Dat’AIDS Cohort Study

19. CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome

20. Zoster after Cyclophosphamide for Systemic Lupus Erythematosus or Vasculitis: Incidence, Risk Factors, and Effect of Antiviral Prophylaxis

21. Protection of Healthcare Workers Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection

22. IL-7 immunotherapy for progressive multifocal leukoencephalopathy in a patient with already controlled HIV-1 infection on antiretroviral therapy

23. Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort

24. Long-term safety and vaccine-induced seropositivity in healthy volunteers from HIV vaccine trials

25. Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection

26. Added value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography for the diagnosis of post-operative instrumented spine infection

27. Progressive Dementia Revealing an Atypical Encephalitis: Neuroimaging Aspects

28. Once‐daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS ‐165 DARULIGHT study

29. Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV

30. Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort

31. Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen

32. Psychiatric and substance use disorders in HIV/hepatitis C virus (HCV)-coinfected patients: does HCV clearance matter? [Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) HEPAVIH CO13 cohort]

33. Performance Testing of PCR Assay in Blood Samples for the Diagnosis of Toxoplasmic Encephalitis in AIDS Patients from the French Departments of America and Genetic Diversity of Toxoplasma gondii: A Prospective and Multicentric Study

34. A case report of isolated lymphadenopathy revealing localized leishmanial lymphadenopathy in an asthenic 25-year-old man

35. Contribution of molecular diagnosis to the management of cutaneous leishmaniasis in travellers

36. Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study

37. Does transient cART started during primary HIV infection undermine the long-term immunologic and virologic response on cART resumption?

38. Blunted Response to Combination Antiretroviral Therapy in HIV Elite Controllers: An International HIV Controller Collaboration

39. Toxoplasmic encephalitis IRIS in HIV-infected patients: a case series and review of the literature

40. Routine testing to reduce late HIV diagnosis in France

41. Missed opportunities for HIV testing in newly-HIV-diagnosed patients, a cross sectional study

42. Incidence and Risk Factors of First-Line HAART Discontinuation: Is it Worth Choosing Competing Risk or Standard Survival Approaches?

43. Personal protection against biting insects and ticks

44. Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults

45. Correlates of late HIV diagnosis: implications for testing policy

Catalog

Books, media, physical & digital resources